Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00614653|
Recruitment Status : Completed
First Posted : February 13, 2008
Last Update Posted : August 1, 2016
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Cancer||Drug: Bevacizumab Drug: Erlotinib Drug: Capecitabine Radiation: Radiation Therapy||Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||17 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I Trial of Preoperative Radiotherapy With Concurrent Bevacizumab, Erlotinib and Capecitabine for Locally Advanced Pancreatic Cancer|
|Study Start Date :||January 2008|
|Actual Primary Completion Date :||July 2016|
|Actual Study Completion Date :||July 2016|
Experimental: Bevacizumab, Erlotinib + Capecitabine
Bevacizumab intravenous (IV) every 2 weeks at 5 mg/kg, Erlotinib 100 mg orally (PO) daily + Capecitabine 400 mg/m2 PO twice daily (BID) only on days of radiation. Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy.
5 mg/kg IV Over 90 Minutes Every 2 Weeks
100 mg by mouth Once Daily on days with radiation.
400 mg/m^2 PO Twice Daily on days with radiation.
Other Name: Xeloda
Radiation: Radiation Therapy
Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy
- Highest Tolerated Dose of Capecitabine, Erlotinib Hydrochloride, and Bevacizumab + Radiation [ Time Frame: 5 1/2 Weeks ]
Any of these events considered a dose-limiting toxicity.
- Any grade 4 hemorrhage, grade 2 pulmonary or CNS hemorrhage
- Cardiac arrhythmia
- Grade 4 congestive heart failure
- Grade 4 hypertension or reversible posterior leukoencephalopathy syndrome (RPLS)
- Grade 4 nephrotic syndrome
- Grade 4 diarrhea
- Grade 4 rash
- Pulmonary adverse event related to erlotinib
- Bowel perforation
- Symptomatic Grade 4 venous thromboembolic event, or any grade arterial thromboembolic event
- Wound dehiscence requiring medical or surgical intervention
- Determination by the investigator that it is no longer safe for the subject to continue therapy
- Response Rate of Addition of Bevacizumab and Erlotinib to Capecitabine-Based Chemoradiation [ Time Frame: 4 to 6 weeks after radiation treatment ]Complete response (CR) — complete disappearance of clinical evidence of a tumor. Partial response (PR) — 50% or greater decrease in sum of products of the longest perpendicular diameters of all measured lesions compared to baseline. Stable disease (SD) — no significant change in disease status. Progressive disease (PD) — a 25% increase in the area of malignant lesions >2 cm2 or in sum of products of the longest perpendicular diameters of individual lesions in a given organ site. If only one lesion is available for measurement, a 50% increase in the size if the area of the lesion was 2 cm2. The appearance of new lesions will also constitute progressive disease. Comparisons of tumor size made with previous smallest measurement in patients who have attained a partial response or with baseline measurements in patients with stable disease. Tumor progression also defined as significant clinical deterioration that cannot be attributed to treatment or other medical conditions.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00614653
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Sunil Krishnan, MD||M.D. Anderson Cancer Center|